Free Newsletter
Expanded indication for GSK's Boostrix approved
GlaxoSmithKline received approval from the FDA to market Boostrix for adults. The vaccine, which is designed to protect against tetanus, diphtheria and pertussis (whooping cough), was previously approved for ages 10-18. GSK now has the green light to use the booster in adults ages 19-64 as well. Boostrix will join a line of GSK vaccines for adults which also include vaccines against hepatitis A and B and the flu. Release
Comments
Post new comment
Paid Research Reports
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
- Pharmaceuticals: United States Industry Guide
- Generic Benchmarking: Brand Erosion at Patent Expiry
- Key Players in Pharmaceutical Contract Manufacturing: Market developments, outsourcing hotspots and growth strategies
More Research Reports >>
Click here to get the FierceVaccines email newsletter for FREE!
Be the first to comment